Peripheral retinal degeneration

Summary

Peripheral retinal degeneration (MONDO:0001451) is a disease (an umbrella term covering 6 Mondo subtypes). A subtype of retinal degeneration — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	peripheral retinal degeneration
Mondo ID	MONDO:0001451
DOID	DOID:12161
ICD-10-CM	H35.4
ICD-11	1518234440
NCIT	C34919
SNOMED CT	405721006
UMLS	C1320640
MedGen	232938
Is cancer (heuristic)	no

Also known as: peripheral degeneration of retina · peripheral retinal Degeneration

Disease family

This is a subtype of retinal degeneration. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal degeneration › peripheral retinal degeneration

Related subtypes (5): macular degeneration, retinoschisis, inherited retinal dystrophy, cone dystrophy 5, X-linked, cone dystrophy 1, X-linked

Subtypes (6): pseudoretinitis pigmentosa, senile reticular retinal degeneration, Blessig’s cysts, retinal lattice degeneration, cobblestone retinal degeneration, secondary vitreoretinal degeneration

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.